Benzinga
06 Apr 2026, 17:41 UTC · 29w ago
Why Is Viridian Therapeutics Stock Sinking Monday?
Impact · against what's priced in
Viridian Therapeutics faces a significant valuation hit as Phase 3 efficacy for elegrobart missed investor expectations, while Amgen's TEPEZZA reinforced its competitive dominance in the TED market. The impact on VRDN is tempered slightly by a near-term PDUFA date for veligrotug, while Amgen's results validate its market position.
- VRDN−0.70
No priced-in read yet
- In context
Phase 3 responder rates for elegrobart (36-45% placebo-adjusted) fell significantly short of the 51-73% range expected by investors, threatening the drug's commercial competitiveness.
Read from the article alone
Search tags
